GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma – Genetic Engineering News

GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma
Genetic Engineering News
GlaxoSmithKline (GSK) and Theravance are reporting mostly positive results from two studies for Relovair in chronic obstructive pulmonary disease (COPD) and asthma. Relovair met its primary endpoint in one of two replicate studies in COPD comparing it
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational MarketWatch (press release)
GSK lung drug has mixed results but filing on trackReuters
GSK's Relovair on track for COPD drug filing; talks on asthma in US ongoingMedCity News
FierceBiotech –4-traders
all 28 news articles »

View full post on asthma – Google News

Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy – Genetic Engineering News

Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy
Genetic Engineering News
The funds will enable Cytos to conduct a global multicenter Phase IIb trial with its lead product CYT003-QbG10 in patients suffering from allergic asthma as well as to advance the rest of its pipeline. This transaction completes the financial
Cytos revives lead program in $40M financing deal with Amgen, venBioFierceBiotech

all 2 news articles »

View full post on asthma – Google News

Johns Hopkins Launches Study of Genetic Drivers of Asthma in Blacks – Diverse: Issues in Higher Educatio


Diverse: Issues in Higher Educatio

Johns Hopkins Launches Study of Genetic Drivers of Asthma in Blacks
Diverse: Issues in Higher Educatio
With a disproportionate share of medical research previously enrolling mainly White study participants, this Black-focused asthma research represents an essential departure. “The genetic and genomic roots are significant,” said Dr. Fernando Martinez,

View full post on asthma – Google News

AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials – Genetic Engineering News


Proactive Investors USA & Canada

AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
Genetic Engineering News
Dynavax Technologies will receive a $3 million payment from AstraZeneca to fund the initiation of clinical trials with their partnered asthma drug AZD 1419. The payment comes as part of the firms' amended collaboration to accelerate the start of
AstraZeneca, Dynavax amend agreement to accelerate development of asthma drugProactive Investors USA & Canada
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for AsthmaMarketWatch (press release)
Dynavax Technologies Corporation partners with AstraZeneca to advance AZD 1419 Middle East North Africa Financial Network
Bizjournals.com (blog)
all 15 news articles »

View full post on asthma – Google News

Genetic clue to asthma disclosed: Research – HealthJockey.com

Genetic clue to asthma disclosed: Research
HealthJockey.com
Asthma is strikingly common and professionals believe that locating the exact cause may aid in developing new treatment strategies. More recently, researchers from the Lung Institute of WA (LIWA) have seemingly disclosed 2 new genetic variants that
New Genetic Variants = Treatment for AsthmaIvanhoe

all 4 news articles »

View full post on asthma – Google News